Company profile: Spirogen
1.1 - Company Overview
Company description
- Provider of novel, sequence-selective DNA minor groove-binding molecules and proprietary pyrrolobenzodiazepine (PBD) technology, including PBD-based ADC payloads and PBD dimers that cross-link DNA to block replication and kill cancer stem cells. Offers licensing of PBD technology and research collaborations/partnerships to develop PBD-based ADCs designed to deliver potent anticancer agents to cancer cells for different cancer treatments.
Products and services
- PBD ADC Payloads: Engineers proprietary PBD-based antibody-drug conjugate payloads that deliver potent anticancer agents to cancer cells using DNA minor groove-binding mechanisms
- PBD Dimers: Architects sequence-selective minor groove-binding molecules that cross-link DNA strands, block replication, and kill cancer stem cells for highly potent antitumor activity
- Licensing of PBD Technology: Offers ADC-focused licenses to select partners to use PBD technology for developing antibody-drug conjugates leveraging DNA minor groove-binding payloads
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spirogen
Rovers
HQ: The Netherlands
Website
- Description: Provider of cancer-screening medical devices, designing, developing, and manufacturing self-sampling and diagnostic tools including Evalyn Brush for at-home HPV screening; Anex Brush for anal cancer screening; Orcellex Brush for oral cancer screening; Viba-Brush and Delphi Screener for cervical cancer self-sampling; and Cervex-Brush for comprehensive cervical cell collection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rovers company profile →
Sanarus
HQ: United States
Website
- Description: Provider of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas; the Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and the ImarC tissue marker system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanarus company profile →
Pionyr
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics that enhance antitumor immunity by targeting the tumor microenvironment. Utilizes novel target discovery and antibody generation platforms and its Myeloid Tuning approach. Programs include PY314 (TREM2) to deplete tumor-associated macrophages, PY159 (TREM1) to repolarize them to counteract immunosuppression, and PY265 (MARCO) to activate immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pionyr company profile →
PDC Line Pharma
HQ: France
Website
- Description: Provider of clinical-stage active cancer immunotherapies based on an allogeneic plasmacytoid dendritic cell line (PDC*line) loaded with cancer antigens, including PDC*lung01, a therapeutic vaccine for non-small cell lung cancer used with anti-PD-1 to induce specific immune responses, and GeniusVac-Mel4, a vaccine designed to prime and expand antitumor T-cells in melanoma patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PDC Line Pharma company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spirogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spirogen
2.2 - Growth funds investing in similar companies to Spirogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spirogen
4.2 - Public trading comparable groups for Spirogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →